Demand Big Pharma stop denying access to an HIV prevention medication

This past spring, the Food and Drug Administration (FDA) approved lenacapavir — a new medication that people can take to prevent HIV infections before they are exposed, as well as to treat multi-drug-resistant HIV.

It’s highly effective, but there is a problem: Gilead Sciences, a pharmaceutical company, controls access to lenacapavir.

And instead of making this lifesaving medicine available to everyone who needs it, Gilead is using patents, licensing carve-outs, price secrecy, and regulatory delays to protect its profits.

Tell the CEO of Gilead: Don’t prevent communities in need from getting lenacapavir. Denying access costs lives.

Send Your Email

First Name

Last Name

Email Address

Address, line 1

City

State

ZIP Code

Mr.

Daniel

O'Day

Gilead Sciences

Mr. O'Day,

I’m concerned that Gilead is failing to provide access to lenacapavir for people in Latin American and Caribbean countries. This drug saves lives, and that means that lives will continue to be lost to preventable HIV infections without it. In order to open access to lenacapavir and save lives, I ask you to:

-Register for regulatory approval broadly right away. There is no reason to apply in some  countries and leave others behind.

-Adopt fair and transparent pricing of $40 for a year of lenacapavir in all low and middle income countries, don’t require non-disclosure agreements, and release detailed information on your pricing. Countries should be able to get their people what they need without paying ruinous amounts of money. At $40, far more people will be able to access lenacapavir.

-Withdraw patent applications that block the entry of generic versions of lenacapavir or local production that could benefit Latin American countries.

Lenacapavir is a major achievement and everyone around the world should be able to benefit from it. Please open up access to lenacapavir and save millions of lives.

{user_data~First Name} {user_data~Last Name}
{user_data~City}, {user_data~State}

General

Unsubscribe me from all future emails

Please select your email preferences